Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 1, 2007

KineMed and Roche Enter Biomarker Collaboration

  • KineMed and Roche will collaborate to jointly validate KineMed's technology that helps transfer therapeutic agents into advanced clinical studies. KineMarker™ measures the on-mechanism activity of compounds in whole body systems in animals and man.

    The companies will clinically validate the KineMarker of collagen synthesis, a therapeutic target underlying tissue fibrosis, in an undisclosed disease area.

    “Fibrosis is a critical process underlying important diseases affecting major organ systems, including the lungs, kidneys, and liver,” points out David Fineman, president and CEO of KineMed. “The research collaboration with Roche will help to establish our approach as a possible surrogate for an important indication and as a means for monitoring on-mechanism activity of drug candidates in ensuing clinical studies.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »